Conditions: Lennox-Gastaut Syndrome
Keywords: Epilepsy Seizures
Allocation: NA | Intervention model: SINGLE_GROUP
Enrollment: 54
Healthy volunteers: no

Brief summary:
To investigate the safety of long term administration of E2080 in the patients with Lennox-Gastaut syndrome who completed the E2080-J081-304 Study.

Detailed description:

Arms:
arm 1: Ralfinamide was administered orally twice daily after breakfast and dinner. Participants on placebo in Study 304 were titrated over to rufinamide within 2 weeks during the Conversion Period. As a general rule, the dose of rufinamide at the end of the Conversion Period was maintained throughout the Maintenance Period.

Interventions: intervention 1: Rufinamide
Intervention descriptions: intervention 1: The target dosage is approximately 45 mg/kg/day, taken orally twice a day.

Protocol document: